Background: Several pharmacological treatments are recommended by guidelines with
moderate to high evidence for the treatment of diarrhea-predominant irritable bowel …

Background: The global prevalence of Irritable bowel syndrome (IBS) is estimated to be as
high as 15% and a number of different non-pharmacological and pharmacological …

Abstract Background & Aims: Multiple pharmacologic treatments are available for the
management of irritable bowel syndrome (IBS), and a large body of evidence has been …

Conclusion: The umbrella reviews will assess the reliability of the evidence so that doctors
and patients can make better medical choices. PROSPERO registration number …

Background & Aims Irritable bowel syndrome (IBS) is a common functional gastrointestinal
disorder associated with significant disease burden. This American Gastroenterological …

Introduction Non-pharmacological treatments are used in the management of irritable bowel
syndrome, and their effectiveness has been evaluated in multiple meta-analyses. The …

Background Irritable bowel syndrome (IBS) is multifactorial in nature, and a wide range of
therapies is available to manage symptoms of this common disorder. Aim To provide an …

Introduction: Irritable bowel syndrome with diarrhea (IBS-D) is among the most common
functional gastrointestinal (GI) disorders and is associated with impaired quality of life …

Irritable bowel syndrome (IBS) causes gastrointestinal symptoms such as abdominal pain,
bloating, and bowel pattern abnormalities, which compromise patients' daily functioning …

Introduction: Irritable bowel syndrome (IBS) is one of the most common gastrointestinal
disorders with a 9–23% prevalence estimated in the general population. Patients can be …